Targets › FGFR3
35 programs from 30 companies in 105 trials: 58 Phase 2, 32 Phase 1, 15 Phase 3; Oncology, Gastroenterology, Other; next expected readout Nov 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. (UniProt, P22607)
Open in Phaseline: the race on FGFR3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| TransThera Sciences (Nanjing) | TT-00420 (tinengotinib) Fibroblast growth factor receptor (FGFR) inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 3 | Cholangiocarcinoma; Cholangiocarcinoma Metastatic; Breast Cancer; Prostate Cancer (CRPC) | Dec 2026 |
| Exelixis | Zanzalintinib (XL092) Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL | FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRA | Phase 3 | Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| Xynomic Pharmaceuticals | Pazopanib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory … | Dec 2026 |
| Johnson & Johnson (Janssen) | Erdafitinib (TAR-210) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 3 | Urothelial Cancer; Non-Muscle Invasive Bladder Neoplasms; Urothelial Carcinoma; Advanced Malignant Solid Neoplasm … | Dec 2026 |
| Johnson & Johnson (Janssen) | Pasritamig FGFR3 inhibitor | FGFR3 | Phase 3 | Prostatic Neoplasms, Castration-Resistant; Metastatic Castration-resistant Prostatic Neoplasms; Prostatic Neoplasms; Metastatic Castration-resistant Prostate Neoplasms | Jan 2027 |
| National Cancer Institute (NCI) | Pazopanib Hydrochloride Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Clear Cell Renal Cell Carcinoma; Foregut Neuroendocrine Tumor; Solid Neoplasm | Feb 2027 |
| Eli Lilly | Vepugratinib (LY3866288) FGFR3 inhibitor | FGFR3 | Phase 3 | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms | Jun 2027 |
| AB Science | Masitinib Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FGFR3, KIT, PDGFRB, PDGFRA | Phase 3 | Amyotrophic Lateral Sclerosis | Dec 2027 |
| Tyra Biosciences | Dabogratinib (TYRA-300) FGFR3-selective tyrosine kinase inhibitor | FGFR3 | Phase 2 | Low-grade NMIBC; Achondroplasia; Low Grade Upper Tract Urothelial Carcinoma; Healthy … | Nov 2026 |
| Taiho Oncology | Futibatinib (TAS-120) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Advanced Cholangiocarcinoma; Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Advanced/Metastatic Cancer; Biliary Tract Neoplasms … | Dec 2026 |
| Tianjin Medical University Cancer Institute and Hospital | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Gastrointestinal Cancer | Dec 2026 |
| Shanghai Zhongshan Hospital | HRS-4642 FGFR1/2/3/4 inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Biliary Tract Cancer; Pancreatic Cancer | Dec 2026 |
| Sameek Roychowdhury | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Advanced Pancreatic Carcinoma | Dec 2026 |
| Tianjin Medical University Cancer Institute and Hospital | Bemotuzumab Anti-FGFR3 monoclonal antibody | FGFR3 | Phase 2 | Small Cell Lung Cancer (SCLC) | Jan 2027 |
| University of Utah | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Mar 2027 |
| UNICANCER | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Solid Tumor, Miscellaneous | Jun 2027 |
| Mehmet Akce | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Intrahepatic Cholangiocarcinoma | Jul 2027 |
| National Cancer Institute (NCI) | Rogaratinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Locally Advanced Gastrointestinal Stromal Tumor | Jul 2027 |
| Ohio State University Comprehensive Cancer Center | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Locally Advanced Ampulla of Vater Carcinoma | Dec 2027 |
| Haitao Zhao, MD | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Biliary Tract Cancer (BTC) | Dec 2027 |
| Lund University Hospital | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Dedifferentiated Liposarcoma | Dec 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Donafenib Multi-kinase inhibitor with activity against FGFRs, VEGFR, and RET | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Hepatocellular Carcinoma | Jan 2028 |
| National Cancer Center, Japan | E7090 FGFR inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Advanced or Recurrent Solid Tumors | Mar 2028 |
| Hutchmed | Hmpl-453 (HMPL-453) Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor | FGFR1, FGFR2, FGFR3 | Phase 2 | Advanced Intrahepatic Cholangiocarcinoma | Jun 2028 |
| Dana-Farber Cancer Institute | Pemigatinib (INCB054828) Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | SDH Gene Mutation | Oct 2028 |
| QED Therapeutics, a BridgeBio company | Infigratinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Achondroplasia | Mar 2030 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Derazantinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Intrahepatic Cholangiocarcinoma | – |
| AstraZeneca | Fexagratinib (AZD4547) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 1 | Muscle Invasive Bladder Cancer; Metastatic Breast Cancer | Nov 2026 |
| OHSU Knight Cancer Institute | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
| Cogent Biosciences | CGT4859 selective FGFR2/3 inhibitor | FGFR2, FGFR3 | Phase 1 | Intrahepatic Cholangiocarcinoma (Icc) | Mar 2027 |
| Tyra Biosciences | TYRA-200 FGFR 1/2/3 tyrosine kinase inhibitor | FGFR1, FGFR2, FGFR3 | Phase 1 | Locally Advanced Cholangiocarcinoma | Mar 2027 |
| Eisai | E-7090 (E7090) Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor | FGFR1, FGFR2, FGFR3 | Phase 1 | Hepatic Impairment | Aug 2027 |
| Massachusetts General Hospital | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| Tyra Biosciences | TYRA-430 FGFR inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 1 | Metastatic Hepatocellular Carcinoma | Jan 2028 |
| M.D. Anderson Cancer Center | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 1 | Advanced Cholangiocarcinoma | Feb 2028 |
Non-Muscle Invasive Bladder Neoplasms (3) Colorectal Cancer (3) Hepatocellular Carcinoma (2) Urothelial Cancer (2) Advanced Malignant Solid Neoplasm (2) Advanced Cholangiocarcinoma (2) Advanced Solid Tumor (2) Hepatic Impairment (2) Achondroplasia (2) Intrahepatic Cholangiocarcinoma (2) Renal Cell Carcinoma (2) Leiomyosarcoma or Carcinosarcoma (2)
small molecule (21), mixed (11), antibody (2), protein or peptide (1)
Tyra Biosciences (3) Johnson & Johnson (Janssen) (2) National Cancer Institute (NCI) (2) Tianjin Medical University Cancer Institute and Hospital (2) AstraZeneca (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Taiho Oncology (1) Shanghai Zhongshan Hospital (1) Massachusetts General Hospital (1) Exelixis (1) UNICANCER (1) QED Therapeutics, a BridgeBio company (1) National Cancer Center, Japan (1) Eli Lilly (1) TransThera Sciences (Nanjing) (1) Mehmet Akce (1) University of Utah (1) Hutchmed (1) Cogent Biosciences (1) Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)
FGFR1 (29) FGFR2 (28) FGFR4 (12) KIT (4) PDGFRA (2) CSF1R (2) LCK (2) MET (1) PDGFRB (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.